ST
ALXN

Spot Trading’s Alexion Pharmaceuticals ALXN Stock Holding History

Spot Trading’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$11.4M Sell
81,600
-138,800
-63% -$18.9M 0.2% 85
2017
Q2 		$26.8M Buy
220,400
+216,100
+5,026% +$25.2M 0.53% 12
2017
Q1 		$521K Buy
4,300
+3,700
+617% +$477K 0.02% 1214
2016
Q4 		$73K Buy
600
+500
+500% +$61.2K ﹤0.01% 2314
2016
Q3 		$12K Sell
100
-1,400
-93% -$180K ﹤0.01% 2877
2016
Q2 		$175K Sell
1,500
-46,600
-97% -$6.61M ﹤0.01% 2287
2016
Q1 		$6.7M Buy
48,100
+39,800
+480% +$5.84M 0.12% 209
2015
Q4 		$1.58M Buy
8,300
+4,200
+102% +$734K 0.02% 1167
2015
Q3 		$641K Sell
4,100
-2,400
-37% -$438K 0.01% 1885
2015
Q2 		$1.18M Buy
6,500
+3,200
+97% +$552K 0.01% 1520
2015
Q1 		$572K Sell
3,300
-18,200
-85% -$3.29M 0.01% 2012
2014
Q4 		$3.98M Sell
21,500
-500
-2% -$92.6K 0.02% 946
2014
Q3 		$3.65M Sell
22,000
-3,200
-13% -$526K 0.02% 1142
2014
Q2 		$3.94M Buy
25,200
+5,000
+25% +$789K 0.02% 1135
2014
Q1 		$3.07M Sell
20,200
-17,100
-46% -$2.72M 0.02% 1169
2013
Q4 		$4.96M Buy
37,300
+300
+0.8% +$36K 0.03% 874
2013
Q3 		$4.3M Buy
37,000
+26,900
+266% +$2.95M 0.03% 830
2013
Q2 		$932K Buy
+10,100
New +$973K 0.01% 1958

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Spot Trading's ALXN Position: Q3 2017 in Review

Spot Trading increased its Alexion Pharmaceuticals (ALXN) stake by 17% in Q3 2017, buying an estimated $872K and bringing the position to 43,678 shares worth $6.13M. The position accounts for 0.11% of the portfolio, ranked #216.

Spot Trading first reported a position in ALXN in Q3 2013 and has held it in 9 quarters since. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • Spot Trading held 43,678 shares of Alexion Pharmaceuticals worth $6.13M as of Q3 2017.
  • Spot Trading bought 6,422 Alexion Pharmaceuticals shares in Q3 2017, an estimated $872K.
  • Alexion Pharmaceuticals made up 0.11% of Spot Trading's portfolio in Q3 2017, its #216 holding.
  • Spot Trading first reported a position in Alexion Pharmaceuticals in Q3 2013 and has held it in 9 quarters since.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Spot Trading's 13F filing for Q3 2017, filed 6 Nov 2017.